The 2020 AMR Benchmark Report – concerning findings with questionable framing

  21 February 2020

The stated intention of the AMR Benchmark report is to guide and incentivise pharmaceutical companies to do more to tackle drug-resistance and provide investors interested in investing in a more ethical and sustainable manner, with a guide to how the pharmaceutical industry “manages risks and opportunities” in the field of AMR. By doing a peer to peer comparison of the companies, they hope to encourage them to compete in exceeding each others efforts in addressing AMR.

Further reading: ReAct
Author(s): ReAct
Effective Surveillance  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University

Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!